Details for Patent: RE46791
✉ Email this page to a colleague
Which drugs does patent RE46791 protect, and when does it expire?
Patent RE46791 protects PREVYMIS and is included in three NDAs.
This patent has forty-four patent family members in thirty-six countries.
Summary for Patent: RE46791
| Title: | Substituted dihydroquinazolines |
| Abstract: | The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses. |
| Inventor(s): | Wunberg; Tobias (Solingen, DE), Baumeister; Judith (Wuppertal, DE), Betz; Ulrich (Wuppertal, DE), Jeske; Mario (Wuppertal, DE), Lampe; Thomas (Dusseldorf, DE), Nikolic; Susanne (Monheim, DE), Reefschlager; Jurgen (Oldenburg, DE), Schohe-Loop; Rudolf (Wuppertal, DE), Sussmeier; Frank (Wuppertal, DE), Zimmermann; Holger (Wuppertal, DE), Grosser; Rolf (Leverkusen, DE), Henninger; Kerstin (Wuppertal, DE), Hewlett; Guy (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Lang; Dieter (Velbert, DE), Nell; Peter (Wuppertal, DE) |
| Assignee: | AICURIS ANTI-INFECTIVE CURES GMBH (Wuppertal, DE) |
| Application Number: | 14/682,512 |
|
Patent Claim Types: see list of patent claims | Use; Compound; Process; |
Drugs Protected by US Patent RE46791
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd | PREVYMIS | letermovir | PELLETS;ORAL | 219104-001 | Aug 30, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Msd | PREVYMIS | letermovir | PELLETS;ORAL | 219104-002 | Aug 30, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-001 | Nov 8, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-002 | Nov 8, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: RE46791
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Germany | 103 19 612 | May 2, 2003 |
International Family Members for US Patent RE46791
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1622880 | ⤷ Sign Up | 300933 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1622880 | ⤷ Sign Up | LUC00070 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 1622880 | ⤷ Sign Up | 2018C/015 | Belgium | ⤷ Sign Up |
| European Patent Office | 1622880 | ⤷ Sign Up | 122018000080 | Germany | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
